Found: 7
Select item for more details and to access through your institution.
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
- Published in:
- Experimental Hematology & Oncology, 2015, v. 4, n. 1, p. 1, doi. 10.1186/s40164-015-0021-2
- By:
- Publication type:
- Article
Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
Estimands for overall survival in clinical trials with treatment switching in oncology.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 1, p. 150, doi. 10.1002/pst.2158
- By:
- Publication type:
- Article
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 2, p. 324, doi. 10.1002/pst.2079
- By:
- Publication type:
- Article
Response to comments on "Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects" by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18:287‐303, DOI: 10.1002/pst.1923
- Published in:
- Pharmaceutical Statistics, 2020, v. 19, n. 5, p. 736, doi. 10.1002/pst.2021
- By:
- Publication type:
- Article
Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects.
- Published in:
- Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 287, doi. 10.1002/pst.1923
- By:
- Publication type:
- Article
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
- Published in:
- British Journal of Haematology, 2016, v. 173, n. 6, p. 938, doi. 10.1111/bjh.13644
- By:
- Publication type:
- Article